"How integrated data platforms can help find the best-suited patients for cancer studies and reduce the burden on care teams"
The terms “personalized medicine” and “precision medicine” have been in common use for more than 20 years. In 2005, personalized medicines only represented 5% of new molecular entities (NME) approved by the FDA, but in 2015 that number had increased to 42%, with most occurring in oncology.1 By 2018, more than 55% of all oncology clinical trials involved the use of a precision medicine biomarker, compared to 15% in 2000.2 The therapeutic benefit of these medicines is now clear, and the economic benefits are also becoming evident. However, significant challenges remain in bringing these precision medicines to the right patients at the right time.Our website contains links to websites owned and operated by third parties. If you use these links, you leave our website. These links are provided for your information and convenience only and are not an endorsement by Deep Lens of the content of such linked websites or third parties. Deep Lens has no control over the contents of any linked website and is not responsible for these websites or their content or availability.